| Cash Flow | 2025-06-30 |
|---|---|
| Impairment of right-of-use assets | 108,759 |
| Prepaid expenses | -1,160 |
| Other liabilities | 709,665 |
| Lease liabilities | -4,925 |
| Deposits | -49,129 |
| Accrued expenses | 163,396 |
| Accounts payable | 339,199 |
| Net income (loss) | -2,257,890 |
| Change in right-of-use assets | 17,994 |
| Net cash used in operating activities | -873,513 |
| Proceeds from note payable | 700,000 |
| Net cash provided by financing activities | 700,000 |
| Net (decrease) in cash, cash equivalents and restricted cash | -173,513 |
Entero Therapeutics, Inc. (ENTO)
Entero Therapeutics, Inc. (ENTO)